Leo Pharma receives UK approval for Adtralza

Efforts to receive approvals for Leo Pharma's eczema treatment Adtralza are continuing, and have now been rewarded by permission to launch the drug on the UK market.

Photo: Leo Pharma / PR

While Leo Pharma awaits news on the fate of Adtralza in the US in the wake of a rejection from the Food and Drug Administration (FDA) earlier in the year, the company has positive news from the United Kingdom.

In connection with the final approval given by the European Medicines Agency (EMA), the Danish firm has now also received authorization to market the drug in the UK from the Medicines and Healthcare products Regulatory Agency (MHRA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs